Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical utility of an NGS-based oncochip for therapeutic decision in metastatic breast cancer (SHARP)
2017-003216-39Phase 2Active
- Sponsor
- European Institute of Oncology
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selumetinib, olaparib and bicalutamide in breast cancer and breast neoplasia (2 arms), sponsored by European Institute of Oncology. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
selumetinibolaparibbicalutamide
03
Conditions
breast cancerbreast neoplasia
Beyond the preview
Go deeper on 2017-003216-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003216-39.